Free Trial

Decent risk-on move across....>

GLOBAL MARKET/OPINION
GLOBAL MARKET/OPINION: Decent risk-on move across global equity markets, with US
10y yields also edging higher as Gilead Sciences reports that their Remdesivir
drug met the primary endpoint in a NIAID study on the drug's effectiveness in
treating COVID-19.
- E-mini S&P shoots to a new recovery high up at 2918.75 in the initial
response, although some upside has been tempered by US GDP data showing the
initial economic weakness from the Coronavirus outbreak.
- Gilead do, however, warn that Remdesivir is not yet licensed or approved
anywhere globally and has not yet been demonstrated to be safe or effective for
the treatment of COVID-19.
MNI London Bureau | +44 203-865-3809 | edward.hardy@marketnews.com
MNI London Bureau | +44 203-865-3809 | edward.hardy@marketnews.com

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.